经黏膜下隧道内镜切除食管平滑肌瘤的疗效分析  

Clinical efficacy of submucosal tunneling endoscopic resection for esophaugus leiomyoma

作　　者：孙娟[1] 成宏伟[1] 黄震[1] 焦胜[1] 唐娟[1] 

机构地区：[1]蚌埠医学院附属泰兴市人民医院消化内科,江苏泰兴225400

出　　处：《现代肿瘤医学》2017年第16期2595-2597,共3页Journal of Modern Oncology

摘　　要：目的:探讨经黏膜下隧道内镜切除术(STER)治疗食管平滑肌瘤的临床疗效及安全性。方法:回顾性分析2013年01月至2016年05月经黏膜下隧道内镜切除术治疗的52例食管平滑肌瘤患者资料,观察手术成功率、安全性、并发症及临床疗效等。结果:本组52例病例均成功完成手术,手术时间30~90 min,平均时间48 min。术中共4例发生穿孔,1例术后发生气腹转普外科治疗,余3例均经保守治疗后痊愈。术后随访1~38个月,平均随访21个月。无一例病变残留或复发。结论:STER治疗食管平滑肌瘤安全有效,具有广阔的应用前景。Objective：To analysis the curative effect and risk of submucosal tunneling endoscopic resection （STER）for esophaugus leiomyoma.Methods：Success rate,safety,complication rate and prognosis of 52 patients with esophaugus leiomyoma,who were treated by STER,from January 2013 to May 2016 were analyzed retrospectively.Results：All 52 cases successfully received submucosal tunneling endoscopic resection.The operation time were 30~90 min（mean 48 min）.During operation,4 cases had perforation.1 case transferred to department of general surgery because of pneumoperitoneum.The others were recovered by conservation treatment.All patients were followed up for 1 to 38 months（mean 21 months）.None of cases had residual disease or recrudescence.Conclusion：As a minimally invasive treatment for esophaugus leiomyoma,STER is safe and effective.It has a broad application prospect.

关 键 词：经黏膜下隧道内镜切除术 食管 平滑肌瘤 

分 类 号：R735.1[医药卫生—肿瘤]